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Preimplantation genetic
diagnosis: why are obstetric
and neonatal risks increased?
The need for more dataIn this issue of Fertility and Sterility, Bay et al. (1) reported a
national, multicenter, obstetric and neonatal follow-up eval-
uation after preimplantation genetic diagnosis (PGD). They
drew their data from the Danish Medical Birth Registry, the
Danish health registers, and themedical records of all children
born after gestational weeks 21 þ 6. In this way, they
compared obstetric and neonatal outcomes in children born
after PGD, children born after in vitro fertilization/intracyto-
plasmic sperm injection (IVF-ICSI), and children born after
spontaneous conception (SC).
They examined the data for 149 PGD children (126 preg-
nancies), and from that period a total of 36,115 children born
after IVF-ICSI, and 909,624 children born after SC. The em-
bryo biopsies had all been performed at the cleavage stage
(day 3). The investigators did not specify whether the transfers
were all performed during the fresh cycle or even after a thaw-
ing/warming cycle. The PGD pregnancies had statistically
signiﬁcantly increased obstetric risks such as placenta praevia
and cesarian delivery when compared with the SC pregnan-
cies. No differences were found when PGD was compared
with IVF-ICSI pregnancies except for a higher risk of cesarian
delivery.
Babies born after PGD had statistically signiﬁcantly
higher neonatal risks such as preterm birth, shorter gestation,
and longer neonatal admission compared with SC children.
Risks for all neonatal outcomes were comparable between
PGD and IVF-ICSI, although the PGD children had longer
neonatal admissions.
The authors stated that the small sample size was the
main limitation of their study, and we agree: 149 studied
cases are not enough to draw conclusions. However, they
are enough, in our opinion, to point to a negative behavior,
especially when the data are indicating an increased negative
impact. There is still debate about whether assisted reproduc-
tion technology (ART) treatments per se can increase obstetric
and neonatal risks. In this study, it did indeed seem to be
increased risks, both obstetric and neonatal.
Both groups of patients undergoing PGD and IVF-ICSI
treatments were older than women conceiving spontane-
ously. Age of women undergoing an ART cycle has been
claimed to be the major cause of the reduced birth rate and
the increased obstetric and neonatal risks. Even in this study,
the PGD and IVF-ICSI patients were older than women
conceiving spontaneously, so this could be the reason why
the risks are increased in the two study groups.
Wemberg et al. (2) recently published a study in which
they compare ART and SC in women of different age groups.
The obstetric risks (such as hypertensive disorders, placenta
praevia, and placental abruption) were all higher in the
ART group for all ages. The poor neonatal outcomes (such1328as low birth weight, very low birth weight, and small for
gestational age) were highest among the ART children as
well. However, the women's age did not seem to be the
reason for increased obstetric and neonatal disorders in the
Bay study's groups.
Furthermore, Bay et al. (1) made an important subanal-
ysis comparing PGD-IVF and SC. No differences were found
except for placenta praevia. Further, they compared PGD-
IVF and standard IVF and found no differences in obstetric
or neonatal risks. By contrast, when they compared PGD-
ICSI versus SC they found higher obstetric and neonatal
risks in the former. When comparing PGD-ICSI versus
ICSI, the former had shorter gestational lengths and an
increased risk for low birth weight, cesarean delivery, and
low birth weight. The results would seem to point to PGD
itself potentially increasing the risk of gestational and
neonatal disorders; however, the PGD-ICSI group comprised
couples with monogenic disorders. When they compared SC
versus SC in couples with a monogenic disease, the obstetric
and neonatal risks were higher in the latter. For this reason,
authors speculated that the monogenic inheritable disorders
per se could be responsible for the increased risks, that the
biopsy could be a safe procedure, at least at the cleavage
stage.
Liebaers et al. (3) studied 581 PGD/preimplantation ge-
netic screening cases performed with cleavage-stage biopsies,
and they concluded that biopsy did not add risk factors to the
health of singleton children. Scott et al. (4) found cleavage-
stage biopsy impairs the implantation potential of the em-
bryos, whereas trophectoderm biopsy had no measurable
impact.
With all this in mind, does the biopsy potentially impact
the embryo's viability, or does it have no affect at all? In other
words, is it possible that the biopsy could reduce the develop-
mental potential and the implantation of the embryo while
not affecting the potentiality of the embryo in terms of
increasing obstetric or neonatal risks? Unfortunately, the
cases that Bay et al. examine are insufﬁcient to give us an
answer.
Another important question we must ask is, Were any of
the pregnancies obtained by vitriﬁed/warmed embryos? In a
recent report, Jing et al. (5) described a statistically signiﬁ-
cantly higher incidence of pregnancy hypertension in pa-
tients who underwent a frozen-embryo transfer (FET) of
biopsied blastocysts compared with women who received
fresh biopsied cleavage embryos (9.0% vs. 2.3%). A similar
outcome was obtained with frozen-thawed biopsied cleavage
embryos (9.1%). Previous studies have highlighted that FET is
associated with placenta-related adverse pregnancy out-
comes such as gestational hypertension, preeclampsia, and
placenta accrete. So FET would seem to be an important factor
in the increased incidence of gestational hypertension and its
related obstetric disorders.
Thus, it is important to know whether some of the chil-
dren in the follow-up study by Bay et al. were born after
FET. If this was the case, we should calculate the incidence
of obstetric and neonatal disorders in the groups differently.
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To conclude, we wish to highlight some important points.
First, the study by Bay et al. (1) is important because they not
only reported results obtained in PGD cycles but cross linked
them with national registries of SC and IVF-ICSI babies.
Studies that compare outcomes for new techniques with natu-
rally conceived pregnancies are extremely valuable.
Second, pregnancies with IVF and ICSI have a higher
incidence of obstetric and neonatal disorders, and ICSI ap-
pears to be the major cause of these disorders. Thus, it is
important to counsel couples undergoing PGD that they
must undergo ICSI as well to obtain the embryos.
Third, Bay et al. (1) concluded their report with a sugges-
tion that the biopsy per se does not increase the risk; rather,
the underlying parental genetic condition is related to the
adverse obstetric and neonatal outcomes. However, in our
opinion, 48 cases of monogenic inherited disorders are not
enough to draw any conclusions.
We also believe that it is important to better deﬁne the
incidence of frozen/vitriﬁed pregnancies. In this particular
cohort of treatments, in fact, we might ﬁnd a higher incidence
of obstetric and neonatal disorders. Although in the literature
studies do not always arrive at the same results and conclu-
sions, in the majority of cases the pregnancies obtained after
FET seem to be at higher risk of poor outcomes than those af-
ter a fresh embryo transfer.
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